PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known				
Application Number	10/071032			
Filing Date February 8, 2002				
First Named Inventor	Richard Dennis Dyer, et al			
Group Art Unit	Unknown			
Examiner Name	Unknown			
Attorney Docket Number	A0000425-01-CFP			

				U.S. PATENT DOCU	MENTS	
Examiner Initials	Cite No.1	U.S. Patent Docum Kind (Number (If Inc.	Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
71/1	V,	5,082,838		Naka, et al	01/21/1992	514/2/1,1
	·/	5,817,819		Furuya, et al	10/06/1998	546/114
		5.948.780		Peterson, Jr., et al	09/07/1999	514/255
TNT	V	6.008.243		Bender. et al	12/28/1999	514/422
				·		
					ļi	
			-			
	\dashv				+	
			\vdash		 	
						
				•		
T	1					
	T					
					l i	

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docum Number ⁴	nent Kind Code ⁶ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6			
TWI	1	wo	95/35296		Takatani, et al	12/28/1995		1			
	V,	wa	01/63244 A1		Chen, et al	08/30/2001		T			
	V,	EP	0 404 525 B1		Naka, et al	05/15/1996					
	V	GB	2 097 396 A		Seivaku. et al	11/03/1982					
		DE	41 37 437 A1		Furrer, et al	05/19/1993					
TNI	Z	EP	0 404 525 A		Naka. et al	12/27/1990		ļ			
		\vdash						+			
											

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/071032 NFORMATION DISCLOSURE February 8, 2002 Filing Date Richard Dennis Dyer, et al STATEMENT BY APPLICANT First Named Inventor Unknown **Group Art Unit** Unknown **Examiner Name** (use as many sheets as necessary) of **Attorney Docket Number** A0000425-01-CFP Sheet 3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361,					
)	/	CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25 -					
	/	CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654					
		DERWENT ABSTRACT, 96-068630/07, "New fused imidazole cpds possess inhibitory activity of adhesion molecule expression (Eng.)"					
	i/	DERWENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating anteriosclerosis"					
	/	DERWENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto:immune diseases, etc."					
	1	DERWENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs are orally administered antitumour agents without side effects of parent"					
	1	KAUL, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900.					
	1	KAUL, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-ally 1-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498					
	v	KAUL, Von R., et al, "Identfizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", ArzneimForsch/Drug Res., 1982; 32(I)(6); pp 610-612					
THE		BROWN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1972; pp 2385-2391					

Examiner	110	Date		11/200
Signature		Considered	()	10109

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/071032 **INFORMATION DISCLOSURE** February 8, 2002 Filing Date STATEMENT BY APPLICANT Richard Dennis Dyer, et al First Named Inventor Unknown **Group Art Unit** Unknown Examiner Name (use as many sheets as necessary) Attorney Docket Number A0000425-01-CFP of

3

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite land the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the litem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
TM	\	PECORARI, Piergiiogio, et al, "Synthesis And Biological Activity of Pyrimido [2,1-b] [1,3]Thiazine, [1,3]Thiazino[3,2-a]Purine And [1,2,3]Triazolo[4,5-d][1,3]Thiazino[3,2-a]Pyrimidine Derivatives And Thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911			
	7	DE MELO, S. J., et al, "5-flouro (3H) pyrimidine-4-ones: synthese, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques françaises, 1992, 50, n 1, pp 39-51.			
	V	Chem. Abstr. 1992; 117; pp 143023e-COPY-TO FOLLOW De Melo et. al.			
	V	FASKHUTDINOW, et al, Kim. Farm. Zh. 1988; 22(5); pp 557 - GOPY TO FOLLOW			
	·/	Chem. Abstr. 1988; 109; pp 162901r-COPY TO FOLLOW Faskhutdino Vefal	? • •		
TNT	V	TOZKOPARAN, Birsen, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331, (Weinheim, Germany); 1998; pp 201-206			
-					

Examiner Signature	Wom	Date Considered	11	16/	04	
	/					

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

AUS 2 5 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/071,032				
Filing Date	February 8, 2002				
First Named Inventor	Richard Dennis Dyer				
Art Unit	1624				
Examiner Name	Tamthom Ngo Truong				
Attorney Docket Number	A0000425-01-CFP	J			

				DOCUMENTS	Class / Subcle
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
TNT		US- 2003/0004172	01-02-2003	Harter, et al	514/260.1
	1	US- 2003/0078276	04-24-2003	Andrianjara, et al	514/26611
	1	us- 2002/0193377	12-19-2002	Andrianjara, et al	514/248
	V	US- 2003/0144274	07-31-2003	Bunker, et al	514 /223.2
	V	US-2003/0130278	07-10-2003	Gaudilliere, et al	514/228.5
	V	^{US-} 2003/0216402	11-20-2003	Gaudilliere, et al.	514/251
	V	US- 2004/0006077	01-08-2004	Gaudilliere, et al	514/227.8
	V	us- 2004/0063673	04-01-2004	Johnson	514/114
	V	US- 2004/0034054	02-19-2004	Wilson	514/301
	1	^{US-} 2004/0038973	02-26-2004	Nahra et al.	514/243
	V	^{US-} 2004/0039012	02-26-2004	Wilson	514/301
	V	^{US-} 2004/0038994	02-26-2004	Wilson	514/260.1
	V	^{us-} 2004/0043991	03-04-2004	Picard et al.	514/222.8
	V	us-4,419,356	12-06-1983	Debarre et al.	514/259,2
	V	us-4,421,914	12-20-1983	Okamura et al.	544/278
	V	^{us} -4,383,996	05-17-1983	Oba et al.	514/259.2
	V	^{US-} 4,302,585	11-24-1981	Wei et al.	544/247
7NT	1/	^{US-} 10/739,261		Bunker et al.	Filed 12-18-2003
		US-			

		FORE	IGN PATENT DOCI	JMENTS		
Examiner Initiats*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ Number ⁴ Kind Code ⁸ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	1
TNT	\ \ \ \ \ \	WO 02/064599	08-22-2002	Dyer et al		
		WO 02/064598	08-22-2002	Harter, et al		
	Y	WO 02/064080	08-22-2002	Andrianjara, et al		П
	V	WO 02/064572	08-22-2002	Andrianjara, et al		
	V,	WO 03/032999	04-24-2003	Bunker et al.		
TNI		WO 03/033478	04-24-2003	Gaudilliere et al.		

[Examiner	2//	Date	
Signature		Considered	11 - 16 - 0.0
Cignaturo		Considered	11 10 07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)

AUS 2 5 2004 ...

Sheet

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/071,032

Filing Date February 8, 2002

First Named Inventor Richard Dennis Dyer

Art Unit 1624

Examiner Name Tamthom Ngo Truong

Attorney Docket Number A0000425-01-CFP

		·	U. S. PATENT D			
Examiner Initials*	Cite No.1		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevan	
		Number-Kind Code ^{2 (f known)}		-	Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-		······································		
		US-				
		US-				
		US-				
		US-				
		US-		•		
		US-			· · · · · · · · · · · · · · · · · · ·	
		US-				
		US-			 	
-		US-				
		US-		· · · · · · · · · · · · · · · · · · ·		
		US-				
		US-	<u> </u>			
		U\$-	 	······································		
		US-	†			

			IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	₽°
TNT	V	WO 03/076417	09-18-2003	Gaudilliere et al.		厂
	V	WO 2004/000322	12-31-2003	Gaudilliere et al.		
	1/	WO 2004/014384	02-19-2004	Johnson		
	V	WO 2004/014375	02-19-2004	Wilson		
1	ĺ.	WO 2004/014365	02-19-2004	O'Brien et al.		
TNT	V	WO 2004/014908	02-19-2004	Wilson	1	m

Examiner	 Date	
Signature		
Cignataro	Considered	11116/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/071,032				
Filing Date	February 8, 2002				
First Named Inventor	Richard Dennis Dyer				
Art Unit	1624				
Examiner Name	Tanithom Ngo Truong				
Attorney Docket Number	A0000425-01-CFP				

			U. S. PATENT D						
Examiner Initials*	Cite No.1	Cite No. ¹	Cite No.1	Cite No.1	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (F known)}			Figures Appear				
		US-							
		US-							
		US-							
•		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-		· · · · · · · · · · · · · · · · · · ·					
		US-							
		US-		· · · · · · · · · · · · · · · · · · ·					
		US-			· · · · · · · · · · · · · · · · · · ·				
		US-							
		US-		·	····				
		US-							
		US-							
		US-							
		US-			 				

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	۲
TNT	/	WO 2004/014916	02-19-2004	Wilson		
TWT	//	WO 2004/014923	02-19-2004	Picard et al.		
TNI	V	WO 96/38434	12-05-1996	Hupe et al.		Ľ
	ļ					L
		·			1	Г

Examiner		Date	T 7		_
		Date	[<i>[</i>	/	
Signature		Considered	1 71 /	16/04	
	7/// 8/2	Considered	1 11	10/07	
			1 ' /	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUS 2 5 2004

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE or the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known		
Substitute	10r 10m 1449/P10		`.	Application Number	10/071,032	
INFO	RMATION	DIS	CLOSURE	Filing Date	February 8, 2002	
STATEMENT BY APPLICANT				First Named Inventor	Richard Dennis Dyer	
•	dt			Art Unit	1624	_
(Use as many sheets as necessary)				Examiner Name	Tamthom Ngo Truong	
Sheet	4	of	4	Attorney Docket Number	A0000425-01-CFP	

			NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TV	T	/	Office Action from 10/264,764 (PC20536A) mailed 6.16.03	
		V	LOVEJOY et al., "Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors", Nature Structural Biology, 1999, Vol. 6, No. 3, pages 217-221.	
		i/	MOY et al., "High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor", J. Mol. Biol., 2000, Vol. 302, 671-689 •	
			MITCHELL et al., "Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage", J. Clin. Invest., 1996, Vol. 97, No. 3, pages 761-768	
·			NEUHOLD et al., "Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) reduces osteoarthritis in mice", J. Clin. Invest., 2001, Vol. 107, No. 1, pages 35-44.	
		/	DAHLBERG et al., "Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritis Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase 1)", Arthrit. & Rheum., 2000, Vol. 43, No. 3, pages 673-682	
		V	BILLINGHURST et al., "Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selection Inhibition of Type II Collagen Cleavage by Collagenase", Arthrit. & Rheum., 2000, Vol. 43, No. 3, pages 664-672	
			BILLINGHURST et al., "Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage", J. Clin. Invest., 1997, Vol. 99, No. 7, pages 1534-1545	
			HIROTA et al., "Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative Coupling", Heterocycles, 1994, Vol. 37, No. 1, pages 563-570	
TN			PCT International Search Report, PCT/IB02/00313	

Examiner	11.0	Date	111/018
Signature	100 on	Considered	11/16/09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicants.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.